Skip to main content
SpringerLink
Log in

Progesterone Receptor Signaling in the Breast Tumor Microenvironment

  • Chapter
  • First Online:
Tumor Microenvironment

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1329))

Abstract

The tumor microenvironment (TME) is a complex infrastructure composed of stromal, epithelial, and immune cells embedded in a vasculature ECM. The microenvironment surrounding mammary epithelium plays a critical role during the development and differentiation of the mammary gland, enabling the coordination of the complex multihormones and growth factor signaling processes. Progesterone/progesterone receptor paracrine signaling interactions in the microenvironment play vital roles in stem/progenitor cell function during normal breast development. In breast cancer, the female sex hormones, estrogen and progesterone, and growth factor signals are altered in the TME. Progesterone signaling modulates not only breast tumors but also the breast TME, leading to the activation of a series of cross-communications that are implicated in the genesis of breast cancers. This chapter reviews the evidence that progesterone and PR signaling modulates not only breast epitheliums but also the breast TME. Furthermore, crosstalk between estrogen and progesterone signaling affecting different cell types within the TME is discussed. A better understanding of how PR and progesterone affect the TME of breast cancer may lead to novel drugs or a therapeutic approach for the treatment of breast cancer shortly.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L (1999) Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol 17:64–73

    Article  CAS  PubMed  Google Scholar 

  2. Ahmed ISA, Chamberlain C, Craven RJ (2012) S2rpgrmc1: the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin Drug Metab Toxicol 8:361–370

    Article  CAS  PubMed  Google Scholar 

  3. Aldaz CM, Liao QY, LaBate M, Johnston DA (1996) Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 17:2069–2072

    Article  CAS  PubMed  Google Scholar 

  4. Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4:197–201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76:27–36

    Article  CAS  PubMed  Google Scholar 

  6. Arendt LM, Kuperwasser C (2015) Form and function: how estrogen and progesterone regulate the mammary epithelial hierarchy. J Mammary Gland Biol Neoplasia 20:9–25

    Article  PubMed  PubMed Central  Google Scholar 

  7. Arnett-Mansfield RL, DeFazio A, Mote PA, Clarke CL (2004) Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab 89:1429–1442

    Article  CAS  PubMed  Google Scholar 

  8. Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ, Faubion SS, Murad MH (2016) Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev 5:121

    Article  PubMed  PubMed Central  Google Scholar 

  9. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465:798–802

    Article  CAS  PubMed  Google Scholar 

  10. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP (2006) Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci 103:3799–3804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ballare C, Uhrig M, Betchtold T, Sancho E, Domenico MD, Migliaccio A, Auricchio F, Beato M (2003) Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23:1994–2008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973–1979

    Article  CAS  PubMed  Google Scholar 

  13. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 107:2989–2994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Beral V, Collaborators Million Women Study (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

    Article  CAS  PubMed  Google Scholar 

  15. Beral V, Banks E, Reeves G, Wallis M (1997) Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet 349:1103–1104

    Article  CAS  PubMed  Google Scholar 

  16. Beral V, Banks E, Reeves G, Appleby P (1999) Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4:191–210. discussion 10-5

    CAS  PubMed  Google Scholar 

  17. Berstein LM, Yue W, Wang JP, Santen RJ (2011) Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat 128:109–117

    Article  CAS  PubMed  Google Scholar 

  18. Birbrair A, Tan Z, Wang Z-M, Messi ML, Olson JD, Mintz A, Delbono O (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Phys Cell Phys 307:C25–C38

    CAS  Google Scholar 

  19. Bissell MJ, Rizki A, Mian IS (2003) Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol 15:753–762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP (2001) Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8:269–280

    Article  CAS  PubMed  Google Scholar 

  21. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21:359–375

    Article  CAS  PubMed  Google Scholar 

  22. Boonyaratanakornkit V, Hamilton N, Márquez-Garbán DC, Pateetin P, McGowan EM, Pietra RJ (2017) Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol 466:51–72

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Boonyaratanakornkit V, Hamilton N, Marquez-Garban DC, Pateetin P, McGowan EM, Pietras RJ (2018) Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol 466:51–72

    Article  CAS  PubMed  Google Scholar 

  24. Booth BW, Smith GH (2006) Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res 8:R49

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Bravo ML, Pinto MP, Gonzalez I, Oliva B, Kato S, Cuello MA, Lange CA, Owen GI (2015) Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. Endocrine 48:309–320

    Article  CAS  PubMed  Google Scholar 

  26. Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13:385–396

    Article  CAS  PubMed  Google Scholar 

  27. Brisken C, O’Malley B (2010) Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2:a003178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA (2000) Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14:650–654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cahill MA (2007) Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 105:16–36

    Article  CAS  PubMed  Google Scholar 

  30. Cahill MA, Jazayeri JA, Catalano SM, Toyokuni S, Kovacevic Z, Richardson DR (2016) The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochimica et Biophysica Acta (BBA)-Rev Cancer 1866:339–349

    Article  CAS  Google Scholar 

  31. Canfell K, Banks E, Clements M, Kang YJ, Moa A, Armstrong B, Beral V (2009) Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat 117:671–673

    Article  PubMed  Google Scholar 

  32. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, Walsh BW, Chen C, McTiernan A, Investigators Women’s Health Initiative (2008) Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 168:370–377. quiz 45

    Article  CAS  PubMed  Google Scholar 

  33. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, Investigators WHI (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O’Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL (2015a) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women’s health Initiative randomized clinical trials. JAMA Oncol 1:296–305

    Article  PubMed  PubMed Central  Google Scholar 

  35. Chlebowski RT, Aragaki AK, Anderson GL (2015b) Menopausal hormone therapy influence on breast cancer outcomes in the women’s health initiative. J Natl Compr Cancer Netw 13:917–924

    Article  CAS  Google Scholar 

  36. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, Wysolmerski JJ, Millar SE (2004) Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 131:4819–4829

    Article  CAS  PubMed  Google Scholar 

  37. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, Ryu HS, Kim S, Lee JE, Park YH, Kan Z, Han W, Park WY (2017) Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 8:15081

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, TCGA Research Network, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991

    CAS  PubMed  Google Scholar 

  40. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS (2005) A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 277:443–456

    Article  CAS  PubMed  Google Scholar 

  41. Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149:1192–1205

    Article  CAS  PubMed  Google Scholar 

  42. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218–228

    Article  CAS  PubMed  Google Scholar 

  43. Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168

    Article  PubMed Central  Google Scholar 

  44. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O’Malley BW (2002) Reproductive functions of progesterone receptors. Recent Prog Horm Res 57:339–355

    Article  CAS  PubMed  Google Scholar 

  45. Conneely OM, Mulac-Jericevic B, Arnett-Mansfield R (2007) Progesterone signaling in mammary gland development. Ernst Scher Found Symp Proc:45–54

    Google Scholar 

  46. Curtis Hewitt S, Couse JF, Korach KS (2000) Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2:345–352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Daniel AR, Faivre EJ, Lange CA (2007) Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 21:2890–2906

    Article  CAS  PubMed  Google Scholar 

  48. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D’Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506–515

    Article  CAS  PubMed  Google Scholar 

  49. Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA (2009) Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer 16:351–361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Dressing GE, Goldberg JE, Charles NJ, Schwertfeger KL, Lange CA (2011) Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids 76:11–17

    Article  CAS  PubMed  Google Scholar 

  51. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F (2017) Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 75:284–298

    Article  CAS  PubMed  Google Scholar 

  52. Enomoto LM, Kloberdanz KJ, Mack DG, Elizabeth D, Weinberg A (2007) Ex vivo effect of estrogen and progesterone compared with dexamethasone on cell-mediated immunity of HIV-infected and uninfected subjects. J Acquir Immune Defic Syndr 45:137–143

    Article  CAS  PubMed  Google Scholar 

  53. Faivre EJ, Daniel AR, Hillard CJ, Lange CA (2008) Progesterone receptor rapid signaling mediates Ser345 phosphorylation and tethering to Sp1 transcription factors. Mol Endocrinol 22(4):823–837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41–50

    Article  CAS  PubMed  Google Scholar 

  55. Faulkner S, Jobling P, March B, Jiang C, Hondermarck H (2019) Tumor neurobiology and the war of nerves in cancer. Cancer Discov 9:702–710

    Article  CAS  PubMed  Google Scholar 

  56. Fernandez-Valdivia R, Lydon JP (2012) From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol 357:91–100

    Article  CAS  PubMed  Google Scholar 

  57. Fernandez-Valdivia R, Mukherjee A, Ying Y, Li J, Paquet M, DeMayo FJ, Lydon JP (2009) The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol 328:127–139

    Article  CAS  PubMed  Google Scholar 

  58. Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA (2017) Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III. Cancer Res 77:4934–4946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336

    Article  CAS  PubMed  Google Scholar 

  60. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454

    Article  CAS  PubMed  Google Scholar 

  61. Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111

    Article  CAS  PubMed  Google Scholar 

  62. Fu X-D, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T (2008) Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One 3

    Google Scholar 

  63. Fu X-D, Goglia L, Sanchez AM, Flamini M, Giretti MS, Tosi V, Genazzani AR, Simoncini T (2010) Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. Endocr Relat Cancer 17:431

    Article  CAS  PubMed  Google Scholar 

  64. Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean PS (2012) Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res 72:6490–6501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gonzalez-Suarez E (2011) RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol 13:222–228

    Article  CAS  PubMed  Google Scholar 

  66. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103–107

    Article  CAS  PubMed  Google Scholar 

  67. Goodman ML, Trinca GM, Walter KR, Papachristou EK, D’Santos CS, Li T, Liu Q, Lai Z, Chalise P, Madan R, Fan F, Markiewicz MA, Jin VX, Carroll JS, Hagan CR (2019) Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer. J Immunol 202:3076–3086

    Article  CAS  PubMed  Google Scholar 

  68. Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502–519

    CAS  PubMed  Google Scholar 

  69. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150:3318–3326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Greenstein B, Roa R, Dhaher Y, Nunn E, Greenstein A, Khamashta M, Hughes GR (2001) Estrogen and progesterone receptors in murine models of systemic lupus erythematosus. Int Immunopharmacol 1:1025–1035

    Article  CAS  PubMed  Google Scholar 

  71. Grimm SL, Hartig SM, Edwards DP (2016) Progesterone receptor signaling mechanisms. J Mol Biol 428:3831–3849

    Article  CAS  PubMed  Google Scholar 

  72. Hansen RK, Bissell MJ (2000) Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. Endocr Relat Cancer 7:95–113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Haslam SZ (1989) The ontogeny of mouse mammary gland responsiveness to ovarian steroid hormones. Endocrinology 125:2766–2772

    Article  CAS  PubMed  Google Scholar 

  74. Haslam SZ, Nummy KA (1992) The ontogeny and cellular distribution of estrogen receptors in normal mouse mammary gland. J Steroid Biochem Mol Biol 42:589–595

    Article  CAS  PubMed  Google Scholar 

  75. Haslam SZ, Shyamala G (1979) Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation. Biochem J 182:127–131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Haslam SZ, Woodward TL (2003) Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res 5:208–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53

    Article  CAS  PubMed  Google Scholar 

  78. Hilton HN, Graham JD, Kantimm S, Santucci N, Cloosterman D, Huschtscha LI, Mote PA, Clarke CL (2012) Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. Mol Cell Endocrinol 361:191–201

    Article  CAS  PubMed  Google Scholar 

  79. Hilton HN, Santucci N, Silvestri A, Kantimm S, Huschtscha LI, Graham JD, Clarke CL (2014) Progesterone stimulates progenitor cells in normal human breast and breast cancer cells. Breast Cancer Res Treat 143:423–433

    Article  CAS  PubMed  Google Scholar 

  80. Hilton HN, Clarke CL, Graham JD (2018) Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol 466:2–14

    Article  CAS  PubMed  Google Scholar 

  81. Howard BA, Gusterson BA (2000) Human breast development. J Mammary Gland Biol Neoplasia 5:119–137

    Article  CAS  PubMed  Google Scholar 

  82. Hughes GC (2012) Progesterone and autoimmune disease. Autoimmun Rev 11:A502–A514

    Article  CAS  PubMed  Google Scholar 

  83. Hughes GC, Clark EA, Wong AH (2013) The intracellular progesterone receptor regulates CD4+ T cells and T cell-dependent antibody responses. J Leukoc Biol 93:369–375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A (2019) RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res 38:12

    Article  PubMed  PubMed Central  Google Scholar 

  85. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O’Malley BW, Lydon JP (2003) Progesterone involvement in breast development and tumorigenesis – as revealed by progesterone receptor “knockout” and “knockin” mouse models. Steroids 68:779–787

    Article  CAS  PubMed  Google Scholar 

  86. Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S, Higaki K, Fujiwara T, Doihara H, Symmans WF, Pusztai L (2014) Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat 143:403–409

    Article  CAS  PubMed  Google Scholar 

  87. Janzen DM, Rosales MA, Paik DY, Lee DS, Smith DA, Witte ON, Iruela-Arispe ML, Memarzadeh S (2013) Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res 73:4697–4710

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Jobling P, Pundavela J, Oliveira SMR, Roselli S, Walker MM, Hondermarck H (2015) Nerve–cancer cell cross-talk: a novel promoter of tumor progression. Cancer Res 75:1777–1781

    Article  CAS  PubMed  Google Scholar 

  89. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696

    Article  CAS  PubMed  Google Scholar 

  90. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature 465:803–807

    Article  CAS  PubMed  Google Scholar 

  91. Joshi PA, Goodwin PJ, Khokha R (2015) Progesterone exposure and breast cancer risk: understanding the biological roots. JAMA Oncol 1:283–285

    Article  PubMed  Google Scholar 

  92. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401

    Article  CAS  PubMed  Google Scholar 

  93. Kawprasertsri S, Pietras RJ, Marquez-Garban DC, Boonyaratanakornkit V (2016) Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells. Cancer Lett 374:279–291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155–192

    Article  CAS  PubMed  Google Scholar 

  95. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055

    Article  CAS  PubMed  Google Scholar 

  96. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH (2010) Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176:2911–2920

    Article  PubMed  PubMed Central  Google Scholar 

  97. Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM (2017) Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget 8:3811–3825

    Article  PubMed  Google Scholar 

  98. Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, Visvader JE, Lindeman GJ, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Graham J, Muscat GE, Clarke CL, Clyne CD (2013) Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat 142:211–223

    Article  CAS  PubMed  Google Scholar 

  99. Knutson TP, Daniel AR, Fan D, Silverstein KAT, Covington KR, Fuqua SAW, Lange CA (2012) Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res 14:R95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Koenig HL, Gong WH, Pelissier P (2000) Role of progesterone in peripheral nerve repair. Rev Reprod 5:189–199

    Article  CAS  PubMed  Google Scholar 

  101. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999a) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323

    Article  CAS  PubMed  Google Scholar 

  102. Kong YY, Boyle WJ, Penninger JM (1999b) Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 77:188–193

    Article  CAS  PubMed  Google Scholar 

  103. Krishnamurthy N, Kurzrock R (2018) Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev 62:50–60

    Article  CAS  PubMed  Google Scholar 

  104. Lamb R, Harrison H, Clarke RB (2007) Mammary development, carcinomas and progesterone: role of Wnt signalling. Ernst Scher Found Symp Proc:1–23

    Google Scholar 

  105. Lange CA (2008) Challenges to defining a role for progesterone in breast cancer. Steroids 73:914–921

    Article  CAS  PubMed  Google Scholar 

  106. Lee HJ, Gallego-Ortega D, Ledger A, Schramek D, Joshi P, Szwarc MM, Cho C, Lydon JP, Khokha R, Penninger JM, Ormandy CJ (2013) Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development 140:1397–1401

    Article  CAS  PubMed  Google Scholar 

  107. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE (2012) Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 72:2028–2035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT (2018) Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer 18:485–499

    Article  CAS  PubMed  Google Scholar 

  109. Macias H, Hinck L (2012) Mammary gland development. Wiley Interdiscip Rev Dev Biol 1:533–557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132:545–553

    Article  CAS  PubMed  Google Scholar 

  111. Mangelsdorf DJ, Tummel C, Beato M, Herrlich P, Schutz P, Umensono K, Blumberg B, Kastner P, Mark M, Chambon P, Evan RM (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Mao G, Wang J, Kang Y, Tai P, Wen J, Zou Q, Li G, Ouyang H, Xia G, Wang B (2010) Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. Endocrinology 151:5477–5488

    Article  CAS  PubMed  Google Scholar 

  113. Mattsson W (1983) Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat 3:231–235

    Article  CAS  PubMed  Google Scholar 

  114. McGowan EM, Clarke CL (1999) Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol 13:1657–1671

    Article  CAS  PubMed  Google Scholar 

  115. McGowan EM, Weinberger RP, Graham JD, Hill HD, Hughes JA, O’Neill GM, Clarke CL (2003) Cytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels. J Mol Endocrinol 31:241–253

    Article  CAS  PubMed  Google Scholar 

  116. McGowan EM, Saad S, Bendall LJ, Bradstock KF, Clarke CL (2004) Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts. Breast Cancer Res Treat 83:211–220

    Article  CAS  PubMed  Google Scholar 

  117. McGowan EM, Russell AJ, Boonyaratanakornkit V, Saunders DN, Lehrbach GM, Sergio CM, Musgrove EA, Edwards DP, Sutherland RL (2007) Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res 67:8942–8951

    Article  CAS  PubMed  Google Scholar 

  118. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746–1752

    Article  CAS  PubMed  Google Scholar 

  119. Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O’Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O’Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirstrom K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R (2016) Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep 6:18517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F (1998) Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008–2018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Mikels AJ, Nusse R (2006) Wnts as ligands: processing, secretion and reception. Oncogene 25:7461–7468

    Article  CAS  PubMed  Google Scholar 

  122. Miki Y, Clyne CD, Suzuki T, Moriya T, Shibuya R, Nakamura Y, Ishida T, Yabuki N, Kitada K, Hayashi S, Sasano H (2006) Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of in situ steroidogenesis. Cancer Lett 244:24–33

    Article  CAS  PubMed  Google Scholar 

  123. Mohammed H, Alasdair Russell I, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A (2015) Progesterone receptor modulates ERα action in breast cancer. Nature 523:313–317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Moore MA (2001) The role of chemoattraction in cancer metastases. BioEssays 23:674–676

    Article  CAS  PubMed  Google Scholar 

  125. Moreno TD, Cerliani JP, Croci DO, Mendez-Huergo SP, Moses F, Rabinovich GA, Salatino M (2015) Abstract 465: progestin-driven regulatory T cells directly promote an aggressive and metastatic phenotype in triple-negative breast cancer. Cancer Res 75:nr465

    Article  Google Scholar 

  126. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, Byamugisha J, Padian N, Celentano DD, Salata RA (2010) Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 24:1778–1781

    Article  CAS  PubMed  Google Scholar 

  127. Mote PA, Balleine RL, McGowan EM, Clarke CL (1999) Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 84:2963–2971

    CAS  PubMed  Google Scholar 

  128. Mote PA, Balleine RL, McGowan EM, Clarke CL (2000) Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum Reprod 15(Suppl 3):48–56

    Article  CAS  PubMed  Google Scholar 

  129. Mote PA, Bartow S, Tran N, Clarke CL (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72:163–172

    Article  CAS  PubMed  Google Scholar 

  130. Mote PA, Graham JD, Clarke CL (2007) Progesterone receptor isoforms in normal and malignant breast. Ernst Scher Found Symp Proc:77–107

    Google Scholar 

  131. Moulton VR (2018) Sex hormones in acquired immunity and autoimmune disease. Front Immunol 9:2279

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  132. Muenst S, Mechera R, Däster S, Piscuoglio S, Ng CKY, Meier-Abt F, Weber WP, Soysal SD (2017) Pregnancy at early age is associated with a reduction of progesterone-responsive cells and epithelial Wnt signaling in human breast tissue. Oncotarget 8:22353

    Article  PubMed  PubMed Central  Google Scholar 

  133. Mukherjee A, Soyal SM, Li J, Ying Y, He B, DeMayo FJ, Lydon JP (2010) Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. FASEB J 24:4408–4419

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Mulac-Jericevic B, Conneely OM (2004) Reproductive tissue selective actions of progesterone receptors. Reproduction 128:139–146

    Article  CAS  PubMed  Google Scholar 

  135. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM (2003) Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A 100:9744–9749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Munoz-Cruz S, Togno-Pierce C, Morales-Montor J (2011) Non-reproductive effects of sex steroids: their immunoregulatory role. Curr Top Med Chem 11:1714–1727

    Article  CAS  PubMed  Google Scholar 

  137. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123:21–27

    Article  PubMed  Google Scholar 

  138. Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schroder CP (2015) Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. Pharmacol Ther 147:63–79

    Article  CAS  PubMed  Google Scholar 

  139. Nusse R, Brown A, Papkoff J, Scambler P, Shackleford G, McMahon A, Moon R, Varmus H (1991) A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 64:231

    Article  CAS  PubMed  Google Scholar 

  140. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Munoz P, Vinals F, Tometsko M, Branstetter D, Dougall WC, Gonzalez-Suarez E (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72:2879–2888

    Article  CAS  PubMed  Google Scholar 

  141. Papanastasiou AD, Sirinian C, Plakoula E, Zolota V, Zarkadis IK, Kalofonos HP (2017) RANK and EGFR in invasive breast carcinoma. Cancer Genet 216-217:61–66

    Article  CAS  PubMed  Google Scholar 

  142. Pateetin P, Pisitkun T, McGowan E, Boonyaratanakornkit V (2020) Differential quantitative proteomics reveals key proteins related to phenotypic changes of breast cancer cells expressing progesterone receptor A. J Steroid Biochem Mol Biol 198:105560

    Article  CAS  PubMed  Google Scholar 

  143. Prazeres PHDM, Leonel C, Silva WN, Rocha BGS, Santos GSP, Costa AC, Picoli CC, Sena IFG, Gonçalves WA, Vieira MS (2020) Ablation of sensory nerves favours melanoma progression. J Cell Mol Med 24(17):9574–9589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Pundavela J, Roselli S, Faulkner S, Attia J, Scott RJ, Thorne RF, Forbes JF, Bradshaw RA, Walker MM, Jobling P (2015) Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer. Mol Oncol 9:1626–1635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Rajaram RD, Brisken C (2012) Paracrine signaling by progesterone. Mol Cell Endocrinol 357:80–90

    Article  CAS  PubMed  Google Scholar 

  147. Rao S, Cronin SJF, Sigl V, Penninger JM (2018) RANKL and RANK: from mammalian physiology to cancer treatment. Trends Cell Biol 28:213–223

    Article  CAS  PubMed  Google Scholar 

  148. Rizzoli R, Yasothan U, Kirkpatrick P (2010) Denosumab. Nature Publishing Group

    Book  Google Scholar 

  149. Robinson DP, Klein SL (2012) Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav 62:263–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Robinson GW, Hennighausen L, Johnson PF (2000) Side-branching in the mammary gland: the progesterone–Wnt connection. Genes Dev 14:889–894

    Article  CAS  PubMed  Google Scholar 

  151. Rothenberger NJ, Somasundaram A, Stabile LP (2018) The role of the estrogen pathway in the tumor microenvironment. Int J Mol Sci 19

    Google Scholar 

  152. Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217–227

    Article  CAS  PubMed  Google Scholar 

  153. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32

    Article  CAS  PubMed  Google Scholar 

  154. Samson M, Porter N, Orekoya O, Hebert JR, Adams SA, Bennett CL, Steck SE (2016) Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat 155:3–12

    Article  CAS  PubMed  Google Scholar 

  155. Sathyamoorthy N, Lange CA (2020) Progesterone and breast cancer: an NCI workshop report. Horm Cancer 11:1–12

    Article  PubMed  Google Scholar 

  156. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Schramek D, Sigl V, Penninger JM (2011) RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188–194

    Article  CAS  PubMed  Google Scholar 

  158. Schwartz M, Zhang Y, Rosenblatt JD (2016) B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer 4:40

    Article  PubMed  PubMed Central  Google Scholar 

  159. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE (2006) Generation of a functional mammary gland from a single stem cell. Nature 439:84–88

    Article  CAS  PubMed  Google Scholar 

  160. Shi Z, Arai KY, Jin W, Weng Q, Watanabe G, Suzuki AK, Taya K (2006) Expression of nerve growth factor and its receptors NTRK1 and TNFRSF1B is regulated by estrogen and progesterone in the uteri of golden hamsters. Biol Reprod 74:850–856

    Article  CAS  PubMed  Google Scholar 

  161. Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang Y-F, Dembo AG, Schoenfelt K, Vadhi R, Qiu X (2018) Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. Oncotarget 9:4282

    Article  PubMed  Google Scholar 

  162. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E (2014) Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 124:292–299

    Article  CAS  PubMed  Google Scholar 

  163. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439:993–997

    Article  CAS  PubMed  Google Scholar 

  164. Szekeres-Bartho J (2018) The role of progesterone in Feto-maternal immunological cross talk. Med Princ Pract 27:301–307

    Article  PubMed  PubMed Central  Google Scholar 

  165. Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, Zhao L, An X, Du X, Chen X, Wang S, Xia G, Wang B (2008) Induction of regulatory T cells by physiological level estrogen. J Cell Physiol 214:456–464

    Article  CAS  PubMed  Google Scholar 

  166. Tan IJ, Peeva E, Zandman-Goddard G (2015) Hormonal modulation of the immune system – a spotlight on the role of progestogens. Autoimmun Rev 14:536–542

    Article  CAS  PubMed  Google Scholar 

  167. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C (2013) Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5:182ra55

    Article  PubMed  CAS  Google Scholar 

  168. Thomas P, Yefei P, Dong J, Groenen P, Kelder J, De Vlieg J, Zhu Y, Tubbs C (2007) Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor α subtypes and their evolutionary origins. Endocrinology 148:705–718

    Article  CAS  PubMed  Google Scholar 

  169. Truong TH, Dwyer AR, Diep CH, Hu H, Hagen KM, Lange CA (2019) Phosphorylated progesterone receptor isoforms mediate opposing stem cell and proliferative breast cancer cell fates. Endocrinology 160:430–446

    Article  CAS  PubMed  Google Scholar 

  170. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25

    Article  CAS  PubMed  Google Scholar 

  171. Wang S, Counterman LJ, Haslam SZ (1990) Progesterone action in normal mouse mammary gland. Endocrinology 127:2183–2189

    Article  CAS  PubMed  Google Scholar 

  172. Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, Jacobs IJ (2013) The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol 14:1226–1232

    Article  CAS  PubMed  Google Scholar 

  173. Wiebe JP (2006) Progesterone metabolites in breast cancer. Endocr Relat Cancer 13:717–738

    Article  CAS  PubMed  Google Scholar 

  174. Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HA (2013) Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors. Breast Cancer Res 15:R38

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Willemse PH, van der Ploeg E, Sleijfer DT, Tjabbes T, van Veelen H (1990) A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 26:337–343

    Article  CAS  PubMed  Google Scholar 

  176. Woodward TL, Xie JW, Haslam SZ (1998) The role of mammary stroma in modulating the proliferative response to ovarian hormones in the normal mammary gland. J Mammary Gland Biol Neoplasia 3:117–131

    Article  CAS  PubMed  Google Scholar 

  177. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS (2007) ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 49:391–402.e2

    Article  PubMed  Google Scholar 

  178. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM (2014) Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 371:2457–2466

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  179. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP (2011) Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126:113–120

    Article  CAS  PubMed  Google Scholar 

  180. Xing F, Saidou J, Watabe K (2010) Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 15:166–179

    Article  CAS  Google Scholar 

  181. Yu S, Yang X, Zhu Y, Xie F, Lu Y, Yu T, Yan C, Shao J, Yu G, Mo F (2015) Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci Rep 5:1–10

    Google Scholar 

  182. Zbuk K, Anand SS (2012) Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66:1–7

    Article  PubMed  Google Scholar 

  183. Zheng S, Huang J, Zhou K, Xiang Q, Zhang Y, Tan Z, Simoncini T, Xiaodong F, Wang T (2012) Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. J Cell Mol Med 16:296–305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23(30):7721–7735

    Google Scholar 

  185. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484

    Google Scholar 

  186. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795

    Google Scholar 

  187. Presman DM, Ganguly S, Schiltz RL, Johnson TA, Karpova TS, Hager GL (2016) DNA binding triggers tetramerization of the glucocorticoid receptor in live cells. Proceedings of the National Academy of Sciences 113(29):8236–8241

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand

    Viroj Boonyaratanakornkit

  2. Age-Related Inflammation and Degeneration Research Unit, Chulalongkorn University, Bangkok, Thailand

    Viroj Boonyaratanakornkit

  3. Graduate Program in Clinical Biochemistry and Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand

    Viroj Boonyaratanakornkit & Prangwan Pateetin

  4. School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia

    Eileen M. McGowan

  5. Central Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China

    Eileen M. McGowan

  6. UCLA Jonsson Comprehensive Cancer Center and Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA

    Diana C. Márquez-Garbán, L. P. Burton, Nalo Hamilton & Richard J. Pietras

Authors
  1. Viroj Boonyaratanakornkit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eileen M. McGowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana C. Márquez-Garbán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. P. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nalo Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prangwan Pateetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard J. Pietras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Viroj Boonyaratanakornkit .

Editor information

Editors and Affiliations

  1. Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Alexander Birbrair

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boonyaratanakornkit, V. et al. (2021). Progesterone Receptor Signaling in the Breast Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1329. Springer, Cham. https://doi.org/10.1007/978-3-030-73119-9_21

Download citation

Publish with us

Policies and ethics

Search

Navigation